Answers are grounded in this paper and cite their sources.
Objective To compare a newly proposed Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) cut-off for high disease activity (BASDAI≥2.5) with the corresponding Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off (ASDAS≥2.1) as an eligibility criterion for initiating a biologic disease-modifying antirheumatic drug (bDMARD) in routine care patients with axial spondyloarthritis (axSpA). Methods Real-world patients with axSpA initiating their first bDMARD from 9 European registries were analysed. Patients were categorised into 4 subgroups according to the fulfilment of ASDAS and BASDAI criteria at baseline, and treatment effect was assessed at 6 months using several response and remission outcomes. Adjusted logistic regression analyses were performed to determine whether fulfilling ASDAS and BASDAI criteria was associated with achieving the treatment outcomes. Results Of 6,329 patients included, 90.9% fulfilled both ASDAS and BASDAI eligibility criteria at baseline, 2.5% and 2.7% fulfilled either ASDAS or BASDAI criterion alone, while 3.8% fulfilled neither. The subgroup fulfilling both criteria demonstrated the highest responses at 6 months, while the highest remission outcomes were observed in the subgroup fulfilling neither criterion. Fulfilling either criterion at baseline was significantly associated with achieving response outcomes at 6 months, whereas a negative association was observed for remission outcomes. Conclusion In a multinational European cohort, a very large overlap between the BASDAI and the ASDAS eligibility criteria was shown, and the predictive ability of the two criteria to achieve treatment outcomes was comparable. These findings support the use of BASDAI≥2.5 as a criterion for initiating bDMARD therapy in axSpA, particularly when ASDAS is unavailable.
No takes yet. Share an insight, caveat, or question.
Georgiadis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: